লোডিং...
Bias within economic evaluations – the impact of considering the future entry of lower-cost generics on currently estimated incremental cost-effectiveness ratios of a new drug
BACKGROUND: Most economic evaluation models compare a new patented drug (NPRx) to a generic comparator. Drug costs within these models are usually limited to the retail cost of both drugs at the time of model conception. However, the retail cost of the NPRx is expected to drop once generic versions...
সংরক্ষণ করুন:
| প্রকাশিত: | Clinicoecon Outcomes Res |
|---|---|
| প্রধান লেখক: | , , , |
| বিন্যাস: | Artigo |
| ভাষা: | Inglês |
| প্রকাশিত: |
Dove Medical Press
2015
|
| বিষয়গুলি: | |
| অনলাইন ব্যবহার করুন: | https://ncbi.nlm.nih.gov/pmc/articles/PMC4605233/ https://ncbi.nlm.nih.gov/pubmed/26504402 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.2147/CEOR.S90386 |
| ট্যাগগুলো: |
ট্যাগ যুক্ত করুন
কোনো ট্যাগ নেই, প্রথমজন হিসাবে ট্যাগ করুন!
|